Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.37 |
| ▸ | LPL | P06858 | 1/20 | 0.37 |
| ▸ | P4HB | P07237 | 1/20 | 0.36 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CETP | P11597 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | F2 | P00734 | 1/20 | 0.30 |
| ▸ | F11 | P03951 | 1/20 | 0.30 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.30 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.30 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2274567 | 0.79 | LPL (0.42) | LIPGLPLP4HB | |
| SCHEMBL5529616 | 0.78 | LPL (0.34) | LIPGLPLP4HBMEN1KMT2A | |
| SCHEMBL10136962 | 0.75 | EPHX1 (0.42) | LIPGLPLP4HBTDP1LMNA | |
| SCHEMBL18467899 | 0.72 | LPL (0.44) | LIPGLPLP4HB | |
| SCHEMBL19905011 | 0.72 | LPL (0.44) | LIPGLPLP4HB | |
| SCHEMBL8083423 | 0.70 | TSHR (0.41) | P4HB | |
| SCHEMBL1818873 | 0.69 | MAPK1 (0.41) | MAPK1FFAR3AKR1C1LMNAMEN1 | |
| SCHEMBL27921959 | 0.69 | LIPG (0.50) | LIPGLPLP4HBF11 | |
| SCHEMBL26648626 | 0.69 | LIPG (0.59) | MAPK1LIPGLPLP4HBMEN1 | |
| SCHEMBL22580783 | 0.69 | ALDH1A1 (0.41) | MAPK1TDP1LMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1658295-B1 | REGIOSELECTIVE SYNTHESIS OF CCI-779 | WYETH CORP (US) | 2007-06-20 | — | — | EP | claimed |
| US-7153957-B2 | Regioselective synthesis of CCI-779 | WYETH (US) | 2006-12-26 | — | — | US | claimed |
| EP-1658295-A2 | REGIOSELECTIVE SYNTHESIS OF CCI-779 | Wyeth (US) | 2006-05-24 | — | — | EP | claimed |
| WO-2005016935-A2 | REGIOSELECTIVE SYNTHESIS OF CCI-779 | WYETH (US) | 2005-02-24 | — | — | WO | claimed |
| US-20050033046-A1 | Regioselective synthesis of CCI-779 | WYETH | 2005-02-10 | — | — | US | claimed |
| EP-2662376-B1 | PROCESS FOR PREPARING TORISEL | TIANJIN WEIJIE TECHNOLOGY CO LTD (CN) | 2016-11-30 | — | — | EP | disclosed |
| US-9018373-B2 | Method for preparing temsirolimus | TIANJIN WEIJIE TECHNOLOGY CO., LTD. (CN) | 2015-04-28 | — | — | US | disclosed |
| EP-2662377-B1 | PROCESS FOR SYNTHESIS OF TORISEL | TIANJIN WEIJIE TECHNOLOGY CO LTD (CN) | 2015-03-04 | — | — | EP | disclosed |
| US-8822678-B2 | Method for synthesizing temsirolimus | Tianjin Wiejie Technology Co., Ltd. (CN) | 2014-09-02 | — | — | US | disclosed |
| EP-2662377-A1 | PROCESS FOR SYNTHESIS OF TORISEL | Tianjin Weijie Technology Co., Ltd. (CN) | 2013-11-13 | — | — | EP | disclosed |
| EP-2662376-A1 | PROCESS FOR PREPARING TORISEL | Tianjin Weijie Technology Co., Ltd. (CN) | 2013-11-13 | — | — | EP | disclosed |
| US-20130296550-A1 | METHOD FOR SYNTHESIZING TEMSIROLIMUS | TIANJIN WEIJIE TECHNOLOGY CO., LTD. (CN) | 2013-11-07 | — | — | US | disclosed |
| EP-1751168-A1 | PROLINE CCI-779 (PROLINE-RAPAMYCIN 42-ESTER WITH 2,2-BIS (HYDROXYMETHYL) PROPIONIC ACID) AND TWO-STEP ENZYMATIC SYNTHESIS OF PROLINE CCI-779 AND CCI-779 USING MICROBIAL LIPASE | Wyeth (US) | 2007-02-14 | — | — | EP | disclosed |
| US-7153957-B2 | Regioselective synthesis of CCI-779 | WYETH (US) | 2006-12-26 | — | — | US | disclosed |
| EP-1658295-A2 | REGIOSELECTIVE SYNTHESIS OF CCI-779 | Wyeth (US) | 2006-05-24 | — | — | EP | disclosed |
| WO-2005100366-A1 | PROLINE CCI-779 (PROLINE-RAPAMYCIN 42-ESTER WITH 2,2-BIS (HYDROXYMETHYL) PROPIONIC ACID) AND TWO-STEP ENZYMATIC SYNTHESIS OF PROLINE CCI-779 AND CCI-779 USING MICROBIAL LIPASE | WYETH (US) | 2005-10-27 | — | — | WO | disclosed |
| US-20050234086-A1 | Proline CCI-779, production of and uses therefor, and two-step enzymatic synthesis of proline CCI-779 and CCI-779 | WYETH (US) | 2005-10-20 | — | — | US | disclosed |
| WO-2005016935-A2 | REGIOSELECTIVE SYNTHESIS OF CCI-779 | WYETH (US) | 2005-02-24 | — | — | WO | disclosed |
| WO-2005016935-A2 | REGIOSELECTIVE SYNTHESIS OF CCI-779 | WYETH (US) | 2005-02-24 | — | — | WO | disclosed |
| US-20050033046-A1 | Regioselective synthesis of CCI-779 | WYETH | 2005-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130296550-A1 | METHOD FOR SYNTHESIZING TEMSIROLIMUS | RICTOR, MTOR, MAPKAP1 | MAPK1 459/4885LIPG 3308/4885LPL 4335/4885 |
| US-20050234086-A1 | Proline CCI-779, production of and uses therefor, and two-step enzymatic synthesis of proline CCI-779 and CCI-779 | CYP51A1, COASY, ACSL4 | MAPK1 3598/4885LIPG 431/4885LPL 47/4885 |
| US-20050033046-A1 | Regioselective synthesis of CCI-779 | CCR9, CCR7, CCL11 | MAPK1 2449/4885LIPG 3632/4885LPL 4048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.